CTNM

Rating neutralAI Memo

Contineum Therapeutics

As of 2026-04-15/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-04-15 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

6‑12m

Key catalyst

PIPE-791 chronic pain Phase 1b topline in Q2 2026 • 2026-06-30

Expected move: +5%

Biggest risk

This remains a cautious monitoring story because CTNM is still pre-revenue, concentrated in early-stage PIPE-791 execution, and reliant on uncertain binary readouts; PIPE-307 is partner-controlled by J&J, and the prior RRMS Phase 2 study missed prespecified efficacy endpoints, limiting backup-program visibility [#10-K-2026-03-05].

Invalidation

Break below $8 or thesis failure.

What would change my mind?

The constructive case is balance-sheet-backed optionality around PIPE-791: patient dosing has started in PROPEL-IPF, chronic-pain topline is due in Q2 2026, and cash runway extends into mid-2029, giving CTNM time to reach more meaningful clinical inflections without obvious near-term financing stress [#PR-2026-03-05][#10-K-2026-03-05].

Research note

Recommendation

neutral

Confidence

medium

As of

2026-04-15

Base target

$13

p=45%

Bull target

$19

p=30%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

PROPEL-IPF execution can gradually de-risk the lead program
Balance sheet reduces near-term financing pressure
The constructive case is balance-sheet-backed optionality around PIPE-791: patient dosing has started in PROPEL-IPF, chronic-pain topline is due in Q2 2026, and cash runway extends into mid-2029, giving CTNM time to reach more meaningful clinical inflections without obvious near-term financing stress [#PR-2026-03-05][#10-K-2026-03-05].

BearKey bullets

Cash runway is improved but not permanent; clinical setbacks could reopen dilution risk.
PIPE-307 optionality is constrained because J&J controls further development decisions.
PIPE-791 chronic-pain data may fail to show a convincing efficacy signal.

WatchKey bullets

PIPE-791 chronic pain Phase 1b topline in Q2 2026

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $13 (p=45%)

Bull/Bear spread: +53% / -35%

Vs latest close: Bull +53% · Base +5% · Bear -35%

Scenario probabilities

Bull Target: $19 (p=30%)Base Target: $13 (p=45%)Bear Target: $8 (p=25%)

Commentary

Evidence quality is good because primary filings and company IR materials are available, but catalyst density is still low and the deterministic prior is neutral-to-slightly negative. Net view is a low-conviction monitoring stance: balance sheet and near-term readout timing are supportive, yet the thesis still hinges on early clinical proof rather than broad operating momentum.

As of 2026-04-15 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

PROPEL-IPF execution can gradually de-risk the lead program
Balance sheet reduces near-term financing pressure

Scenarios

Bull Target (Scenario probability)

$19 / p=30% prob

Base Target (Scenario probability)

$13 / p=45% prob

Bear Target (Scenario probability)

$8 / p=25% prob

Price $12 as of 2026-06-02

Nearest Scenario: Base (∆ 5%)

Targets vs latest close: Bull +53% · Base +5% · Bear -35%

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-06-30
PIPE-791 chronic pain Phase 1b topline in Q2 2026
Management said topline data from the exploratory PIPE-791 Phase 1b trial in chronic osteoarthritis pain or chronic lower back pain is expected in the second quarter of 2026; the 10-K also frames this study as an efficacy-signal readout for internal development decisions [#PR-2026-03-05][#10-K-2026-03-05].
Prob 45.00% • Move 35.00% • Priced-in 20.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

PROPEL-IPF execution can gradually de-risk the lead program
2026-12-31
Contineum has initiated patient dosing in PROPEL-IPF, a global Phase 2 study of PIPE-791 in approximately 324 IPF patients, while the 10-K projects trial completion in June 2028; steady enrollment and clean execution are the main medium-term fundamental supports before efficacy data arrive [#PR-2026-03-05][#10-K-2026-03-05].
Prob 60% • Move 20% • Priced-in 30%
Balance sheet reduces near-term financing pressure
2026-12-31
The company reported $262.9 million of cash, cash equivalents and marketable securities at December 31, 2025, and guided runway through mid-2029 after the December 2025 upsized equity raise, which lowers immediate financing risk while PIPE-791 data mature [#PR-2026-03-05][#10-K-2026-03-05].
Prob 75% • Move 15% • Priced-in 55%

Risks

Cash runway is improved but not permanent; clinical setbacks could reopen dilution risk.
PIPE-307 optionality is constrained because J&J controls further development decisions.
PIPE-791 chronic-pain data may fail to show a convincing efficacy signal.
PROPEL-IPF enrollment or execution could slip, delaying the lead asset’s path to value realization.

Peers

Symbol	Summary
ACIU	AC Immune is another small-cap clinical-stage CNS biotech; useful as a binary-development comparator, though its indication set is not a close match to CTNM’s IPF/chronic-pain focus.
AVXL	Anavex provides a market-cap and neuro-biotech risk comparator, but it is only a loose operating peer because pipeline biology and catalyst mix differ materially.
ZURA	Zura Bio is a similarly sized clinical-stage biotech that helps frame financing and catalyst volatility, though it is not an indication-pure peer for Contineum.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-04-15

AI Stock Memo: CTNM - Contineum Therapeutics - RankAlpha